What is CellMosaic?
CellMosaic is a specialized biotechnology firm focused on advanced bioconjugation technologies. The company offers a comprehensive suite of products and services, including Antibody Drug Conjugate (ADC) Kits, custom bioconjugation solutions, and bioconjugate drug development. Leveraging proprietary technologies like AqueaTether (AqT), CellMosaic enables the creation of next-generation targeted therapeutics. Its client base comprises pharmaceutical and biotechnology companies seeking high-quality bioconjugation expertise. Established in 2008, CellMosaic has built a reputation for innovation and quality in the bioconjugation field.
How much funding has CellMosaic raised?
CellMosaic has raised a total of $22K across 1 funding round:
Debt
$22K
Debt (2021): $22K with participation from PPP
What's next for CellMosaic?
With its recent capital infusion, CellMosaic is poised for significant scaling and further innovation in targeted therapeutics. The company's strategic focus on bioconjugation, particularly for Antibody Drug Conjugates, aligns with the growing demand for precision medicine. This investment will likely fuel advancements in their proprietary technologies and expand their service offerings, reinforcing their position as a key player in the biopharmaceutical supply chain and enabling them to pursue new drug development partnerships.
See full CellMosaic company page
